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Prostaglandin E2 prevents Helicobacter-induced gastric
preneoplasia and facilitates persistent infection in a mouse model
Abstract
BACKGROUND AND AIMS:: Persistent infection with the human pathogen Helicobacter pylori
increases the risk of gastric cancer. In this study, we investigated the role of cyclooxygenase-2 (COX-2)
and its main product, prostaglandin E(2) (PGE(2)), in the development of Helicobacter-induced gastritis
and gastric cancer precursor lesions. METHODS:: We utilized mouse models of Helicobacter-induced
gastric preneoplasia and vaccine-induced protection to study the effects of COX-2 inhibition and
PGE(2) treatment on the induction of Helicobacter-specific immune responses and gastric premalignant
immunopathology. RESULTS:: COX-2 and PGE(2) are up-regulated upon Helicobacter infection in
cultured epithelial cells and in the gastric mucosa of infected mice. Inhibition of COX-2 activity with
Celecoxib significantly accelerated early preneoplasia; conversely, systemic administration of synthetic
PGE(2) prevented the development of premalignant pathology and completely reversed pre-existing
lesions by suppressing IFN-gamma production in the infected stomachs. The protective effect of PGE(2)
was accompanied by increased Helicobacter colonization in all models. All in vivo effects were
attributed to immunosuppressive effects of PGE(2) on CD4(+) T-helper 1 (Th1) cells, which fail to
migrate, proliferate and secrete cytokines when exposed to PGE(2)in vitro and in vivo. T-cell inhibition
was found to be due to silencing of IL-2 gene transcription, and could be overcome by supplementation
with recombinant IL-2 in vitro and in vivo. CONCLUSIONS:: COX-2-dependent production of PGE(2)
has an important immunomodulatory role during Helicobacter infection, preventing excessive local
immune responses and the associated immunopathology by inhibiting the effector functions of
pathogenic Th1 cells.
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Abstract  
Background and Aims: 
Persistent infection with the human pathogen Helicobacter pylori increases the risk of 
gastric cancer. In this study, we investigated the role of cyclooxygenase-2 (COX-2) and 
its main product, prostaglandin E2 (PGE2), in the development of Helicobacter-induced 
gastritis and gastric cancer precursor lesions. 
Methods: 
We utilized mouse models of Helicobacter-induced gastric preneoplasia and vaccine-
induced protection to study the effects of COX-2 inhibition and PGE2 treatment on the 
induction of Helicobacter-specific immune responses and gastric premalignant 
immunopathology. 
Results: 
COX-2 and PGE2 are up-regulated upon Helicobacter infection in cultured epithelial 
cells and in the gastric mucosa of infected mice. Inhibition of COX-2 activity with 
Celecoxib significantly accelerated early preneoplasia; conversely, systemic 
administration of synthetic PGE2 prevented the development of premalignant pathology 
and completely reversed pre-existing lesions by suppressing IFN-J production in the 
infected stomachs. The protective effect of PGE2 was accompanied by increased 
Helicobacter colonization in all models. All in vivo effects were attributed to 
immunosuppressive effects of PGE2 on CD4+ T-helper 1 (Th1) cells, which fail to 
migrate, proliferate and secrete cytokines when exposed to PGE2 in vitro and in vivo. T-
cell inhibition was found to be due to silencing of IL-2 gene transcription, and could be 
overcome by supplementation with recombinant IL-2 in vitro and in vivo.   
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Conclusions: 
COX-2-dependent production of PGE2 has an important immunomodulatory role during 
Helicobacter infection, preventing excessive local immune responses and the associated 
immunopathology by inhibiting the effector functions of pathogenic Th1 cells. 
 
Key words: Helicobacter pylori; gastric cancer; cyclooxygenase; prostaglandin E2 
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Introduction 
Persistent gastric colonization with the human pathogen Helicobacter pylori causes 
chronic active gastritis in infected individuals and has been linked epidemiologically to 
gastric and duodenal ulcers, gastric mucosa-associated lymphoid tissue lymphoma and 
gastric cancer.1-3 The chronic gastric inflammation induced by H. pylori infection 
constitutes a prerequisite for the formation of preneoplastic and malignant lesions, both in 
humans and in rodent models of Helicobacter induced disease.4, 5 The transformation 
from normal mucosa to gastric cancer occurs via a sequence of precursor lesions starting 
with atrophic gastritis, intestinal metaplasia and dysplasia.6 Using mouse models of 
experimental Helicobacter infection and vaccine-induced protection, we have shown 
recently that stomach-infiltrating CD4+CD25- IFN-J-secreting T-cells play a dual role in 
the Helicobacter-host interaction. On the one hand, these cells are crucial in controlling 
the infection; on the other hand, they promote the development of Helicobacter-induced 
gastric cancer precursor lesions, possibly through a direct effect of IFN-J on gastric 
epithelial cells.7   
The two processes of inflammation and carcinogenesis share a common molecular 
mediator, the cyclooxygenase enzymes. The COX-1 isoform is constitutively expressed 
in most cell types whereas COX-2 is induced in response to proinflammatory stimuli 
such as LPS, IL-1 and TNF-D.8 The most important lipid product of COX-2, 
prostaglandin E2 (PGE2), exerts its effects by binding to the E-prostanoid receptors 1-4 
(EP1-4), which are expressed ubiquitously in most murine tissues.9  
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Several lines of evidence indicate that COX-2-dependent pathways play a role in 
carcinogenesis, especially in the gastro-intestinal tract. Many solid tumors overexpress 
COX-2/PGE2, and polymorphisms in the COX-2 regulatory region determine the carrier’s 
risk of developing several epithelial cancers.10,11 The long term low-level intake of non-
steroidal anti-inflammatory drugs (NSAIDs) inhibiting COX activity reduces the risk for 
colorectal cancer12, 13 as well as gastric cancer.14 Tumor-derived PGE2 is believed to 
promote cancer progression by stimulating cell motility/invasion and tumor-associated 
angiogenesis and by preventing tumor cell apoptosis (reviewed in15, 16). Several pathways 
and signalling networks are activated or enhanced by PGE2; most notably, PGE2 
potentiates Wnt and PPARGsignalling to induce target genes involved in replication and 
survival and triggers cell migration by activation of the EGFR pathway.15 In addition to 
its direct effects on cancer cell biology, PGE2 is known to have strong 
immunosuppressive effects, giving rise to the hypothesis that PGE2 production may allow 
tumors to evade immune surveillance.17  
The reported immunosuppressive effects of PGE2 on CD4+ T-cells, in particular Th1- 
polarized effector T-cells (reviewed in18), prompted us to examine the role of COX-
2/PGE2 in our model of Helicobacter-induced, T-cell-driven gastric preneoplasia. We 
found that inhibition of COX-2 enzymatic activity strikingly accelerated the development 
of gastritis and premalignant gastric lesions, and that, conversely, systemic administration 
of synthetic PGE2 prevented premalignant changes. The protective effects of PGE2 in our 
model could be attributed to its immunosuppressive effects on CD4+CD25- T-cells, which 
failed to migrate, to proliferate and to secrete IFN-J when exposed to PGE2 in vitro or in 
vivo. Taken together, the data suggest that COX-2/PGE2 dependent pathways are critical 
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in preventing excessive gastric immunopathology by regulating the activity of 
“pathogenic” T-cells. 
Materials and Methods 
Mice, cell culture, bacterial infections and vaccination 
Male C57BL/6, IL-10-/-BL/6 and Ly5.1BL/6 mice (Charles River Laboratories, Sulzfeld, 
Germany) were bred at a Helicobacter-free SPF facility and infected at 5-6 weeks of age. 
All animal experiments were approved by the cantonal veterinary office.  Helicobacter 
strains used for animal experimentation were  H. felis CS1 (ATCC 49179)19 and H. pylori 
strain SS1.20 Mouse infections were performed orally with ~108 bacteria. Primary gastric 
epithelial cells were isolated as previously described;21 the immortalized murine gastric 
epithelial cell line used in this study was also described previously.7 Both cell types were 
grown in DMEM/Ham’s F12 medium (1:1; Gibco) supplemented with 10% FCS and 
infected for 12 hours with H. pylori strains G27 or an isogenic mutant lacking the Cag 
pathogenicity island (PAI), G27'PAI.22 Vaccination of mice was performed as stated in 
the supplemental methods. 
 
Pharmacological treatments 
For inhibition of COX-2, mice were fed a diet supplemented with 1500 ppm Celecoxib 
(for details see Suppl. Methods; Research Diets, New Brunswick, NJ, USA) or an 
identical control diet without the active compound. For PGE2 treatment in vivo, 10Pg of 
16,16-dimethyl PGE2 and 17-phenyl trinor PGE2  was diluted in 100Pl PBS (details in 
Suppl. Methods; Cayman Chemicals, Ann Arbor, Michigan, USA) and injected twice 
intraperitoneally (i.p.) and once combined i.p./orogastrically (o.g.) per week. IL-2 (BD 
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Pharmingen) was injected i.p. 3 times per week (4x104 units per injection; see Suppl. 
Methods). For cell culture experiments, PGE2 was added at 25P0IL-2 was used at 
10ng/ml. 
 
Preparation of gastric tissue and assessment of colonization, gastric IFN-J production, 
Cox-2 expression, neutrophil infiltration and histopathology  
After sacrifice, the stomachs were dissected longitudinally into equally sized pieces. For 
the assessment of H. felis colonization, total genomic stomach DNA was subjected to 
quantitative PCR analysis of the flaB gene, as described previously.7 Quantitative 
analysis of gastric IFN-J expression and Cox-2 expression and activity was performed as 
described in the supplemental methods. Neutrophil infiltration was quantified as 
described.7 Paraffin sections were stained with the histological dyes Giemsa, Alcian Blue 
(AB) and Periodic acid Schiff (PAS) as well as an antibody specific for proliferating cell 
nuclear antigen (PCNA; clone PC10, Zymed Labs) for grading of gastric histopathology 
based on the features described in the updated Sydney classification (see Suppl. 
Methods).23   
 
Lymphocyte proliferation and activation assays 
CD4+CD25- T-cells were immunomagnetically purified from single cell suspensions of 
spleens, mesenteric lymph nodes or stomach sections containing both corpus and antral 
tissue (R&D Systems, Minneapolis, USA). Cells were labelled with 5PM 
carboxyfluorescein succinimidyl ester (CFSE) and stimulated with anti-CD3/CD28 
coated beads. The CFSE dilution was assessed flow cytometrically. IFN-Ȗ secretion was 
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measured by ELISA (BD Biosciences, San Diego, CA, USA). IL-2 and IFN-Ȗ expression 
was determined by RT-PCR using primers specified in the supplemental methods. For 
staining of intracellular IFN-J, cells were stained for CD4 (clone RM4-5, eBioscience, 
San Diego, USA) prior to fixation, permabilization and IFN-Jstaining XMG1.2, BD 
Biosciences, San Diego, CA, USA). FACS analyses were performed on a CyanADP 
instrument (Dako, Glostrup, Denmark). The T-cell migration assay is described in the 
supplemental methods. 
 
Statistical analysis 
P-values were calculated using Graph Pad prism 5.0 software. The significance of 
differences in histopathology scores was calculated by Mann-Whitney test and the 
significance of numerical differences was calculated by Student’s t-test. All in vitro 
assays were analyzed in triplicate and are shown with standard deviations. 
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Results 
Helicobacter infection induces cyclooxygenase-2 (COX-2) and PGE2 in vitro and in vivo 
To assess whether COX-2 and its product PGE2 are induced upon Helicobacter infection 
in cell culture models, we infected primary murine gastric epithelial cells (Figure 1A) and 
immortalized murine gastric epithelial cells (Figure 1B) with wild type H. pylori G27 or 
an isogenic mutant ('PAI) lacking the Cag pathogenicity island, a known virulence 
determinant of pathogenic H. pylori strains.22 In both cell types, COX-2 protein 
expression and PGE2 secretion was induced by H. pylori in a dose-dependent manner, 
and independently of the Cag PAI (Figure 1A-C). PGE2 production was blocked in the 
presence of the COX inhibitor indomethacin (Figure 1C), indicating that it is produced 
exclusively by COX enzymes in this setting. COX-2 and its product PGE2 were further 
also strongly induced in the gastric mucosa of infected compared to uninfected mice 
(Figure 1D and E).   
In order to determine whether mucosal PGE2 concentrations correlate with the degree and 
type of gastric pathology in our model, we selected groups of Helicobacter-infected mice 
based on their predominant pathology. We thus compared mice that showed either 
gastritis, hyperplasia or acidic mucus-positive metaplasia, respectively (for simplicity 
referred to as “metaplasia” in the following; Figure 1F). PGE2 production was 
significantly higher in animals displaying epithelial damage, e.g. hyperplasia and 
metaplasia, compared to those which showed gastritis only (Figure 1F). Our data are 
consistent with previous studies reporting COX-2 expression in H. pylori-infected 
cultured epithelial cells,24 and in gastric preneoplastic and malignant lesions.25  
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COX-2 inhibition during infection aggravates Helicobacter-induced epithelial pathology 
in C57BL/6 mice  
To test if COX-2 activity modulates the formation of Helicobacter-associated chronic 
gastritis and pre-cancerous lesions, we treated H. felis-infected mice with Celecoxib for 3 
months (Figure 2A). Celecoxib specifically targets COX-2 and is believed to act 
predominantly by decreasing PGE2 levels.15 The efficacy of Celecoxib treatment was 
confirmed by a COX-2-specific enzymatic activity assay (Figure 2B). The inhibition of 
COX-2 significantly aggravated H. felis-induced epithelial atrophy and hyperplasia 
compared to infected, untreated counterparts as determined by quantitative 
histopathological scoring of histologically stained sections (Figure 2C). The more severe 
pathology observed under conditions of COX-2 inhibition was accompanied by a 
significant decrease in H. felis colonization (Figure 2D), and a strong increase of the 
gastric expression of the Th1 cytokine IFN-Ȗ (Figure 2E), corroborating both the direct 
correlation between IFN-Ȗ levels and gastric histopathology, and the inverse correlation 
between IFN-Ȗ expression and colonization that we have reported previously.7 In 
conclusion, COX-2 inhibition accelerates the development of Helicobacter-induced early 
gastric cancer precursor lesions while simultaneously reducing the bacterial burden and 
increasing the local expression of IFN-Ȗ, implying that COX-2 and PGE2 may act as 
immune modulators of the Helicobacter-host interaction.  
 
Treatment of Helicobacter-infected mice with synthetic PGE2 inhibits chronic 
inflammation and pre-cancerous lesions 
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To investigate a possible protective effect of COX-2 activity on the H. felis-infected 
gastric mucosa in an independent experimental setup, we treated C57BL/6 mice with 
synthetic PGE2 during 6 or 12 weeks of infection (Figure 3A). To ensure complete 
activation of all PGE2 receptors (EP1-4), we administered a mixture of two synthetic 
PGE2 analogs, 16,16-dimethyl PGE2 and 17-phenyl trinor PGE2 (referred to in the 
following as “PGE2”). The PGE2 treatment prevented the mild to moderate lymphocytic 
infiltration observed after 6 weeks post infection (p.i.; Figure 3A and B) and also 
completely inhibited the moderate to severe chronic inflammation, atrophy, metaplasia 
and/or hyperplasia indicative of 12 week-infected mice (Figure 3A and C). 
Immunohistochemical staining and quantification of proliferating cell nuclear antigen 
(PCNA) reactivity further confirmed the efficient inhibition of epithelial 
hyperproliferation by PGE2 (Figure 3D). Consequently, the decrease in H. felis 
colonization that typically accompanies the onset of severe gastric pathology between 6 
and 12 weeks post infection was prevented by PGE2 treatment (Figure 3E). Long term 
treatment with PGE2 further completely prevented the increase in local IFN-Ȗ production 
that typically occurs in this time frame (Figure 3F) and that precedes the onset of 
pathology and leads to the observed reduction of the bacterial burden.7  
We next tested the protective potential of PGE2 in mice lacking the gene for the anti-
inflammatory cytokine IL-10. IL-10-/- mice launch excessive pro-inflammatory and 
adaptive immune responses to Helicobacter infection;26 as a result, they clear the bacteria 
and develop severe gastritis and preneoplastic lesions already 4 weeks p.i. (Figure 4). 
Treatment of infected IL-10-/- animals with synthetic PGE2 efficiently inhibited the 
development of gastric pathology and hyperproliferation (Figure 4A-C) and prevented 
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neutrophil infiltration into the gastric mucosa (Figure 4D) but did not block clearance of 
the infection (data not shown). As in wild type mice, the local induction of IFN-Ȗ was 
largely prevented by PGE2 treatment in IL-10-/- mice (Figure 4E). The combined results 
indicate that prophylactic PGE2 treatment efficiently inhibits the development of chronic 
gastritis and cancer precursor lesions, possibly by modulating Th1-polarized T-cell 
responses.  
 
Pre-existing gastric cancer precursor lesions in H. felis infected mice can be reversed by 
PGE2 treatment 
To test the effects of PGE2 as a potential therapeutic agent capable of curing pre-existing 
lesions, we infected mice with H. felis for 3 months and verified the efficient induction of 
preneoplastic pathology in a small control group (data now shown). 5 of the remaining 13 
mice received PGE2 for another month (Figure 5A). Interestingly, this treatment 
efficiently reversed pre-existing lesions, reducing the scores of all histopathological 
parameters (Figure 5A and B) and the fraction of corpus area affected by PCNA-positive 
hyperplasia (Figure 5C) as well as neutrophil infiltration (Figure 5D). As in 
prophylactically treated mice, PGE2 had a beneficial, in this case even curative, effect on 
mucosal integrity while at the same time boosting bacterial colonization (Figure 5E). In 
line with all previous results (Figures 3 and 4), the PGE2 treatment significantly reduced 
the local gastric expression of IFN-J (Figure 5F).  
To confirm the regression of pre-existing lesions upon PGE2 treatment during the last of 
4 months of H. felis infection, we repeated the experiment with 3 additional read outs 
(Suppl. Figure 1). As before, the lesions regressed in all PGE2 treated mice compared to 
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the infected control group (data not shown); we further found by flow cytometry that the 
gastric infiltration of leukocytes and CD4+ T-cells had significantly decreased in the 
PGE2 treated group (Suppl. Figure 1A and B). Finally, we examined the presence of Th1- 
polarized, IFN-J-producingCD4+ T-cells in the mesenteric lymph nodes (MLN) by 
intracellular cytokine staining followed by FACS. We found that the 4 month infection 
indeed led to a strong increase of IFN-J-producingCD4+ T-cells in the MLN, which 
could be blocked at least partially by PGE2 treatment (Suppl. Figure 1C). We conclude 
from both studies that systemically administered PGE2 efficiently reverses pre-existing 
gastric cancer precursor lesions, possibly by blocking the priming and activity of Th1-
polarized T-cell responses in the draining lymph nodes.  
  
PGE2 impairs vaccine-induced protection against Helicobacter by blocking local effector 
T-cell responses 
We have shown in the experiments outlined above that PGE2 treatment in vivo boosts 
bacterial colonization and, conversely, that COX-2 inhibition promotes clearance 
(Figures 2D, 3E, 5E). To test whether PGE2 would also impair vaccine-induced 
protection upon challenge infection of immunized mice, we utilized a vaccination 
protocol directed against H. pylori SS1. Indeed, administration of PGE2 during challenge 
impaired the vaccine-induced reduction of bacterial loads (Figure 6A). The infiltration of 
leukocytes and CD4+ T-cells into the gastric mucosa observed in vaccinated/challenge-
infected mice was largely prevented by administration of PGE2 (Figure 6B,C), possibly 
explaining why PGE2-treated mice fail to reduce bacterial colonization. In single cell 
MLN preparations of individual mice (Figure 6D), PGE2 treatment during the challenge 
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phase clearly abolished the vaccination-induced increase of IFN-J-producingCD4+ T-
cells in the MLN (Figure 6D). Taken together, our data imply that PGE2 interferes with 
the T-cell mediated control of Helicobacter infection not only under standard 
experimental infection conditions, but also during a challenge infection after vaccination, 
and that this effect is due to T-cell inhibition in vivo.  
To test whether PGE2 directly interferes with IFN-J production by MLN cells, single cell 
suspensions were cultured in the presence of increasing concentrations of PGE2 (Figure 
6E). PGE2 treatment reduced the infection-dependent secretion of IFN-J into the 
supernatant by on average 43% and 94% at a low and high dose, respectively (Figure 
6E).  We conclude that PGE2 efficiently blocks the production of IFN-J both in vitro and 
in vivo, which may explain why PGE2-treated mice are protected from IFN-J-induced 
preneoplastic pathology and show impaired bacterial clearance, a finding that is 
consistent with our previous report of an inverse link between colonization and 
pathology.7  
 
PGE2 inhibits the migration, activation and effector functions of wild type CD4+ T-cells  
To test the effects of PGE2 on CD4+CD25- T-cell migration we utilized a transwell 
migration assay in which calcein-labeled CD4+CD25- T-cells were allowed to migrate 
towards supernatants of H. pylori-infected immortalized gastric epithelial cells. 
Interestingly, the supernatants of infected cells attracted T-cells more efficiently than 
those of uninfected cells (Figure 7A). The migration could be blocked by addition of 
PGE2 (Figure 7A). In order to assess the effects of PGE2 on the proliferation and 
activation of CD4+ effector T-cells, we stimulated CFSE-labeled CD4+CD25- T-cells 
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with anti-CD3/anti-CD28 mAb-coated beads in the presence or absence of PGE2 (Figure 
7B). The activation and proliferation of T-cells, as assessed by measuring IL-2 receptor D 
chain (CD25) expression and CFSE dilution, was blocked almost completely by PGE2 
(Figure 7B). In vivo pretreatment of five donor mice with PGE2 for one month prior to T-
cell isolation also strongly reduced the T-cell activation and proliferation upon 
CD3/CD28 crosslinking (compare Figures 7B and C). The secretion of IFN-J by 
CD3/CD28-activated T-cells was also blocked by PGE2, both by the direct addition of the 
compound to the cultures and by pretreatment of the donor mice (Figure 7D). These 
results suggest that PGE2 is an effective immunosuppressant capable of blocking the 
activation and proliferation of CD4+ T-cells as well as their ability to secrete IFN-J.  
CD4+ effector T-cell activation and proliferation requires an autocrine positive feedback 
loop of IL-2 secretion and IL-2 receptor activation.27 We therefore asked whether the first 
step in this cascade, the transcriptional activation of the IL-2 gene, could be blocked by 
PGE2. Indeed, PGE2 treatment efficiently inhibited IL-2 and IFNG gene expression 
induced by CD3/CD28 crosslinking (Figure 7E). Therefore, we tested whether adding 
recombinant IL-2 would reverse the effects of PGE2. Indeed, addition of IL-2 was able to 
completely reverse the effects of PGE2 on T-cell activation, proliferation and IFN-J 
secretion (Figure 7C, D). These results suggest that PGE2 inhibits T-cells at least in part 
by interfering with their autocrine IL-2-driven positive feedback loop.  
Based on studies reporting that PGE2 may act as an immunosuppressant by stimulating 
the suppressive activities of regulatory T-cells,28 we speculated that Tregs might be an 
additional target of PGE2 in the control of T-cell-mediated immunopathology in the 
Helicobacter-infected stomach. To examine this possibility, we pre-conditioned 
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immunomagnetically isolated Ly5.2+CD4+CD25+ T-cells with PGE2 for 6 hours prior to 
co-culturing them with CFSE-labeled Ly5.1+ effector T-cells at various ratios. Indeed, we 
found that PGE2 pretreatment modestly enhanced the suppressive capacity of Tregs, 
albeit only at a ratio of suboptimal suppression (Suppl. Figure 2). This piece of data 
suggests that Treg can indeed respond to PGE2 in vitro and become more suppressive as a 
result of PGE2 stimulation.  
 
Recombinant IL-2 reverses the effects of PGE2 in vivo 
In order to investigate whether the observed opposing effects of IL-2 and PGE2 hold true 
in vivo, and to explore whether T-cells are indeed critical targets of PGE2, we utilized the 
above-mentioned IL-10-/- model (Figure 4). In addition to a group treated with PGE2 
only, we also included groups that received i.p. doses of recombinant IL-2 (4x104 units, 3 
times weekly) together with PGE2, or IL-2 alone (Figure 7F). IL-2 administration 
efficiently reversed the protection from gastric pathology conferred by PGE2 (Figure 7F). 
This result suggests that the protective effect of PGE2 on the infected gastric mucosa is 
due to the suppression of T-cell effector functions, which are known to directly trigger 
the atrophic gastritis, hyperplastic and metaplastic transformation that are a hallmark of 
the infection in mice as well as in humans.7   
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Discussion 
In this study we provide experimental evidence that COX-2/PGE2-dependent pathways 
play an important immunomodulating role during the early stages of Helicobacter-
induced gastric pathogenesis, thereby preventing excessive gastric immunopathology. We 
show that systemic administration of PGE2 prevented, and COX-2 inhibition exacerbated, 
Helicobacter-induced atrophic gastritis, epithelial hyperplasia and metaplasia. These 
effects were due to the immunosuppressive effects of PGE2 on T-cells, which failed to 
proliferate and to secrete IL-2 and IFN-Ȗ when exposed to PGE2 in vitro or in vivo. 
Our data are in line with several previous studies reporting exacerbated gastritis in H. 
pylori-infected rodents under conditions of COX-1 or -2 inhibition or deletion of the 
COX-1 or -2 genes.29-32 Similar effects were observed in human trials investigating the 
effects of COX inhibition by aspirin in H. pylori infected, asymptomatic individuals, who 
suffered significantly more from mucosal injury and peptic ulcers than their uninfected 
counterparts.33, 34   
Despite the well-documented side effects of aspirin use on the gastric mucosa, the long-
term, low level use of aspirin or non-aspirin NSAIDs prevents the development of gastric 
cancer; this association holds true even in a large meta-analysis including a total of 9 
studies.14 Similarly, treatment with the COX inhibitor nimesulide prevented a substantial 
portion of chemically induced gastric cancers in H. pylori-infected mice.35 The 
chemopreventive outcome of COX inhibition in studies examining cancer as the end 
point is generally believed to be due to the powerful effects of tumor-derived PGE2 on 
cancer cell survival and invasion, tumor-associated angiogenesis and on anti-tumor 
immunosuppression, all of which promote cancer progression.15  
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We demonstrate here that T-cells, in particular effector subsets of the T-helper 
compartment, can be targeted by PGE2. We have shown in a previous study that 
Helicobacter-induced gastric preneoplastic lesions result from the diffuse infiltration of 
CD4+, Th1-polarized effector T-cells into the gastric lamina propria, where T-cell-
derived IFN-J acts directly on gastric epithelial lineages to promote their 
hyperproliferation and their transformation to intestinal-type cells.7 The effector functions 
of CD4+ T-cells such as proliferation, IFN-J production and migration are blocked upon 
exposure to PGE2 in our models, with the underlying mechanism being a block of IL-2 
gene transcription. Consequently, administration of recombinant IL-2 was sufficient to 
override the protective effects of synthetic PGE2 in vitro and in vivo. The profound effect 
of PGE2 on CD4+ T-cell effector functions, maintained even in explanted T-cells re-
stimulated ex vivo, also explains why PGE2-treated mice are colonized at higher levels 
than untreated counterparts, and show impaired vaccine-induced protection. We conclude 
that PGE2 averts immunopathology in the infected stomach by T-cell suppression, the 
necessary consequence of which is persistent colonization with Helicobacter. In seeming 
contrast to the protective effect of exogenously added PGE2, we observe elevated 
endogenous PGE2 in mice with established atrophy. We believe that this PGE2, which 
may be COX-1 derived, is secreted by the gastric mucosa in an effort to repair the 
mucosal damage,36 but is insufficient to act on T-cells and to prevent further damage or to 
reverse pre-established lesions.  
Our finding that PGE2 treatment protects IL-10-/- mice from gastric pathology argues 
against Treg being the primary target of PGE2-driven immunosuppression as IL-10-/-Treg 
are incapable of blocking the Helicobacter-associated gastritis induced by adoptive 
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transfer of effector T-cells into infected Rag-2-/- recipients.37 However, we did observe 
that Treg became modestly more suppressive in vitro upon pre-treatment with PGE2 as 
demonstrated previously by Sharma et al.;28 this observation suggests that the combined 
effects of PGE2 on effector and regulatory T-cells may together account for the complete 
block in T-cell-driven immunopathology observed in our wild type infection models.  
An intriguing finding of our study was the observed therapeutic effect of PGE2 on 
preexisting lesions, an observation that is seemingly incongruent with studies reporting 
the prevention of gastric cancer by COX inhibition.14, 35 However, it has to be stressed 
that Helicobacter-associated preneoplastic lesions in our mouse models are benign and 
can at least partially be reversed upon antibiotic eradication of the infection.38 Under 
these circumstances, the beneficial effect of PGE2’s suppression of pathogenic T-cells 
apparently outweighs the potential pro-carcinogenic effects that PGE2 may have on 
gastric epithelial cells themselves.32 
In conclusion, our data is consistent with a protective role for PGE2 during the early 
stages of the Helicobacter-induced gastric carcinogenesis sequence; at the molecular 
level, PGE2 blocks the autocrine IL-2-driven positive feedback loop to prevent T-cell 
effector functions that are required both for Helicobacter clearance and for the induction 
of preneoplastic gastric immunopathology.  
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Figure legends 
 
Figure 1: COX-2 protein expression and PGE2 production is induced upon Helicobacter 
infection in vitro and in vivo 
COX-2 protein expression was analyzed by Western blotting of extracts from primary 
murine gastric epithelial cells (A) and an immortalized murine gastric epithelial cell line 
(B) infected for 12h with either H. pylori G27 WT or an isogenic Cag-PAI deficient 
mutant ('PAI) at the indicated MOIs. GAPDH levels are shown as loading controls. 
PGE2 production as assessed by competitive ELISA is shown for supernatants of primary 
cells infected with WT G27, in the presence or absence of 28PM indomethacin (C). For 
the analysis of COX-2 protein expression and PGE2 production in vivo, whole stomach 
extracts were generated from 4 five month H. felis-infected and 3 control C57BL/6 mice 
and subjected to Western blot analysis (D) and PGE2 ELISA (E). F, To determine 
mucosal PGE2 concentrations as a function of pathology, we compared groups that 
showed gastritis only, hyperplasia, or metaplasia to uninfected controls. In E and F, all 
samples were analyzed in triplicate; average values are shown with standard deviations. 
 
Figure 2:  Inhibition of COX-2 by the diet-supplemented inhibitor Celecoxib aggravates 
gastritis and gastric preneoplastic pathology induced by H. felis infection 
C57BL/6 mice were infected for three months with H. felis, or remained uninfected, and 
were either fed a control diet or a diet supplemented with Celecoxib (A). COX inhibition 
was verified by COX activity assay (B). All mice were analyzed with respect to gastric 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 23
histopathology (representative Giemsa-, Alcian Blue- and PAS-stained sections and 
pathology scores are shown; C), H. felis colonization (the average colonization is 
indicated per group; D) and gastric expression of IFN-J (E). Scale bar: 50ȝm. 
  
Figure 3: PGE2 treatment of H.felis infected C57BL/6 wild-type mice inhibits chronic 
inflammation and epithelial pathology  
C57BL/6 mice were infected with H. felis and were treated with PGE2 as indicated (A). 
Mice were euthanized 6 weeks (A,B,E,F) or 12 weeks p.i. (A,C,D,E,F). Representative 
Giemsa-stained sections and a summary of all histopathology scores are shown in A-C; 
representative PCNA-stained sections after 12 weeks of infection, along with their 
quantification, are shown in D. H. felis colonization and gastric IFN-J expression are 
shown in E and F.  
 
Figure 4: PGE2 treatment of H.felis infected IL10-/-BL/6 mice inhibits chronic 
inflammation and epithelial pathology   
IL10-/-BL/6 mice were infected for one month with H. felis and were treated with PGE2 
starting on the day of infection (A). Representative Giemsa-stained sections and 
histopathology scores are shown in A and B; the quantification of PCNA-positive 
hyperplasia is depicted in C. Neutrophil infiltration was quantified by myeloperoxidase 
activity assay (averages of all mice per group are shown with standard deviations, D), and 
gastric IFN-J expression was assessed by real time PCR (E; * not detectable). 
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Figure 5: PGE2 treatment of C57BL/6 mice reverses pre-existing gastric precursor 
lesions 
C57BL/6 mice were infected for a total of 16 weeks with H. felis and treated with PGE2 
for the last month as indicated (A). Representative Giemsa-stained sections and 
histopathology scores are shown in A and B; the quantification of PCNA-positive 
hyperplasia in % of the corpus area is depicted in C. (D) Neutrophil infiltration was 
quantified by myeloperoxidase activity assay. H. felis colonization and gastric IFN-J 
expression are shown in E and F.  
 
Figure 6: PGE2 treatment during challenge infection impairs vaccine-induced clearance 
C57BL/6 mice were vaccinated 4 times and challenged with live H. pylori SS1; some 
mice received PGE2 during the challenge phase as indicated. Non-vaccinated infected 
mice served as controls (A). Colony counts are shown as CFU/stomach (A). B-D, Single 
cell suspensions from stomachs (B, C) and MLN  (D) were generated for 2 uninfected, 4 
control infected, 4 immunized/challenged and 4 immunized/challenged/PGE2 treated 
mice and analyzed individually by flow cytometry. Leukocyte (B) and CD4+ T-cell (C) 
infiltration into the stomach is shown in % of total stomach cells. D, The IFN-J-
producing CD4+ T-cell population in the MLN was quantified by intracellular cytokine 
staining. Averages and standard deviations are shown for every treatment group. E, 
Single cell MLN cultures obtained from 5 H. felis-infected and 2 control mice were 
cultured o/n in the presence or absence of PGE2 (2.5PM or 25PM). IFN-Jsecretion into 
the supernatants was assessed by ELISA (*not detectable).  
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Figure 7: PGE2 treatment inhibits CD4+CD25- T-effector cell migration, activation, 
proliferation and IFN-J secretion in vitro and recombinant IL-2 reverses the effects of 
PGE2 in vivo 
A, 1x105 Calcein-labeled splenic CD4+CD25- T-cells were seeded into transwell 
chambers and allowed to migrate towards supernatants of H. pylori-infected or uninfected 
immortalized gastric epithelial cells in the presence or absence of 25ȝM PGE2. The 
migration was quantified spectrophotometrically; data are displayed with the baseline 
migration of cells towards unconditioned medium set as 1. B-E, CD4+CD25- cells were 
isolated from the combined MLN of 5 infected animals (B,D,E) or of 5 infected animals 
that had been pretreated with PGE2 in vivo for 1 month (C,D). The cells were labeled 
with CFSE and stimulated with ĮCD3/28 coated beads; 25ȝM PGE2 and/or 10ng/ml IL-2 
was added where indicated. The CFSE dilution as a measure of proliferation (lower 
panels of B,C) and CD25 up-regulation as a measure of activation (upper panels of B,C) 
were assessed flow-cytometrically. All culture conditions were analyzed in triplicate; all 
statistical comparisons (+/- anti-CD3/CD28, +/- PGE2, +/- IL-2 in B and C; + anti-
CD3/CD28 with or without PGE2 pretreatment in vivo) revealed significant differences 
(p0.05) for the readouts of CFSE dilution and of CD25 up-regulation. D, The anti-
CD3/CD28-induced secretion of IFN-J into the culture supernatants was measured by 
ELISA for the same cultures as shown in B and C. E, IL-2 and IFN-J expression was 
assessed by semi-quantitative RT-PCR. A representative experiment of 3 (panel A) and 4 
(panels B-E) is shown. F, IL10-/-BL/6 mice were infected for one month with H. felis and 
treated with PGE2 or recombinant IL-2 or a combination of the two. Representative 
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Giemsa-stained sections and histopathology scores are shown. No significant differences 
were observed between IL-2-treated groups +/- PGE2.  
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Figure legends to supplemental figures: 
 
Suppl. Figure 1: Therapeutic PGE2 treatment reduces the numbers of stomach-infiltrating 
leukocytes and CD4+ T-cells and blocks IFN-J production in the MLN 
C57BL/6 mice were infected for three months with H. felis or remained uninfected (n=5). 
A subgroup was treated with PGE2 during the fourth month of infection (n=5), whereas 
the remaining infected mice were left untreated (n=5). Single cell suspensions were 
generated from the stomach and MLN of every mouse and analyzed individually. The 
fraction of infiltrating leukocytes (A) and CD4+ T-cells (B) in the stomachs and the 
fraction of CD4+ IFN-J+ cells in the MLN (C) are shown. Averages and standard 
deviations were calculated per group.  
 
Suppl. Figure 2: PGE2 treatment moderately enhances the suppressive activity of 
CD4+CD25+ T-cells on T-effector cell proliferation 
CD4+CD25- (Ly5.1BL/6) and CD4+CD25+ (Ly5.2BL/6) T-cells were 
immunomagnetically isolated from the MLN of uninfected mice. 1.5x105 CFSE-labeled 
CD4+CD25- cells were stimulated with anti-CD3/CD28 coated beads in the presence or 
absence of 25PM PGE2 (A) or combined at increasing ratios with CD4+CD25+ Treg as 
indicated (B). PGE2 was either added to combined cultures, or Treg were pre-treated for 
6h with PGE2 and then added to CD4+CD25- cells. The proliferation (CFSE dilution) and 
activation (CD25 expression) of T-effector cells was analyzed after three days by FACS. 
In B, only the cells from the upper left quadrant (CD25+, CFSE low) are plotted. All 
cultures were analyzed in triplicate; averages and standard deviations are shown. 
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Supplemental methods 
Assessment of gastric histopathology 
Paraffin sections were stained with the histological dyes Giemsa, Alcian Blue and 
Periodic acid Schiff as well as an antibody specific for proliferating cell nuclear antigen 
(PCNA; clone PC10, Zymed Labs) for grading of gastric histopathology based on the 
features described in the updated Sydney classification.1 We divided each of the three 
categories of the Sydney system (mild, moderate, and severe) into two subcategories as 
proposed by Chen et al.,2 resulting in a scale of 0–6 (none, 0; mild, 1–2; moderate, 3–4; 
severe, 5–6). The definitions of the four histopathological parameters scored were the 
following: chronic inflammation: infiltration of the mucosa and submucosa of the antrum 
and corpus of the stomach with B- and T-lymphocytes; atrophy: loss of specialized, 
terminally differentiated cells of the gastric mucosa, such as parietal, chief and mucus-
producing cells (evident histologically as loss of surface staining with the periodic-acid 
Schiff dye); hyperplasia: hyperproliferation of progenitor cells to compensate for the loss 
of differentiated gastric cells (therefore sometimes called compensatory epithelial 
hyperplasia; detected by PCNA reactivity); acidic mucus producing metaplasia: 
appearance of acidic mucus producing goblet like cells in the gastric corpus mucosa, for 
simplicity reasons here referred to as metaplasia (histologically evident due to Alcian 
Blue positivity).   
 
Quantification of COX-2 expression and enzymatic activity, and PGE2 levels in gastric 
tissues 
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COX-2 expression was assessed by Western blotting (No.160106, Cayman Chemicals, 
Ann Arbor, USA); COX-2 activity was determined using the COX activity Assay Kit 
(No. 760151, Cayman Chemicals) according to the manufacturer’s protocol with addition 
of COX-1 inhibitor. PGE2 was assessed by competitive immunoassay (Assay Designs, 
Ann Arbor, USA) according to the manufacturer’s instructions. 
 
Pharmacological treatments (extended version) 
For inhibition of COX-2, mice were fed a diet supplemented with 1500 ppm Celecoxib 
(D04090202) as described by Jacobi et al.3 (Research Diets, New Brunswick, NJ, USA) 
or an identical control diet (AIN 76A D1000) without the active compound. The average 
daily drug dose per mouse was determined to be 3.7mg based on the quantification of 
food intake per cage. For PGE2 treatment in vivo and in vitro, a stock containing 1mg/ml 
16,16-dimethyl PGE2  and 1mg/ml 17-phenyl trinor PGE2 was prepared in 100% ethanol, 
as described by Hansen-Petrik et al.4. To this end, the methyl acetate in which PGE2 is 
commercially available had to be vacuum-evaporated and then reconstituted in ethanol. 
The stock solution was diluted to 10Pg/100Pl in PBS and injected twice intraperitoneally 
(i.p.) and once combined i.p./orogastrically (o.g.) per week resulting in a total dose of 
30Pg/week/mouse. Control mice were injected with PBS. For IL-2 treatment (BD 
Pharmingen, 50069, Lot 06498) in vivo, we administered 4x104 units per injection as 
proposed by hong.5 Recombinant IL-2 was diluted in PBS and administered 3 times 
weekly i.p.  
 
Vaccination of mice, challenge infection and colony count assay 
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For vaccination, mice were gavaged four times at weekly intervals with 1mg whole cell 
sonicate of Helicobacter pylori strain SS1 together with 10 ȝg cholera toxin as adjuvant 
(List Biologicals, Campbell, CA, USA) prior to challenge infection with 108 CFU H. 
pylori SS1. Mice were sacrificed two weeks post challenge; bacterial colonization was 
assessed by plating of increasing volumes (1, 10 and 100 Pl) of homogenized stomach 
extract on horse blood agar plates followed by colony counting after 5 days of culture 
under microaerophilic conditions as described previously.6 
 
Determination of IL-2 and IFN-Ȗ expression by RT-PCR and real time RT-PCR 
IL-2 and IFN-Ȗ expression was analyzed by RT-PCR using the following primers: IL-2 
forward: 5’GCGCACCCACTTCAAGCT 3’; IL-2 reverse: 5’CCTGCTTACAACAC 
ATAAGGC3’; IFN-J forward: 5’GGTGACATGAAA ATCCTGCAGAGC3’; IFN-J 
reverse: 5’ TCAGCAGCGACTCCTTTTCCGCTT 3’. The quantitative analysis of 
gastric IFN-J expression was performed as described;6 in brief, total RNA was isolated 
from scraped gastric mucosa using RNeasy Mini columns (Qiagen). The corresponding 
cDNA served as template for real time PCR (LightCycler; Roche) using the LightCycler 
480 SYBR Green I master kit (Roche); GADPH expression was determined for 
normalization. 
 
Preparation of protein extracts for COX-2 and PGE2 quantification 
Protein extracts of scraped gastric mucosa were prepared by homogenization in 
extraction buffer (20mM HEPES, 0.4mM NaCl, 25% glycerol, 1mM EDTA, 1mM NaF 
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and 0.1% NP-40, supplemented with protease inhibitors). 10ȝg/ml indomethacine (a 
COX inhibitor; Sigma) was added to all extracts intended for PGE2 quantification. 
 
Transwell migration assay 
CD4+CD25- T-cells were generated as described above and labeled with calcein (BD 
Pharmingen); 105 lymphocytes were seeded onto 96-well format trans-well plates 
(ChemoTx® Disposable Chemotaxis System, Neuro Probe, Gaithersburg, MD) and 
chemoattracted by 30Pl of conditioned medium for 2h at 37°C. The proportion of 
migrated cells was quantified spectrophotometrically.  
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